New challenges and opportunities in nonclinical safety testing of biologics

- Refine use of non-human primates and current experience on the use of minipigs.
- Tissue distribution studies to support PKPD assessment.
- Mechanisms of nonspecific toxicity of ADCs and ways to increase safety margins.
- Significant adverse effects of biologics cannot necessarily always predicted.
- Specifics of noncanonical mAbs like bispecifics and nanobodies.